KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income towards Common Stockholders (2018 - 2025)

Amneal Pharmaceuticals (AMRX) has 8 years of Net Income towards Common Stockholders data on record, last reported at $49.6 million in Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 339.0% year-over-year to $49.6 million; the TTM value through Dec 2025 reached $127.9 million, up 273.17%, while the annual FY2025 figure was $127.9 million, 209.45% up from the prior year.
  • Net Income towards Common Stockholders reached $49.6 million in Q4 2025 per AMRX's latest filing, up from $18.1 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $49.6 million in Q4 2025 and bottomed at -$120.8 million in Q2 2022.
  • Average Net Income towards Common Stockholders over 5 years is -$6.4 million, with a median of $2.3 million recorded in 2021.
  • The widest YoY moves for Net Income towards Common Stockholders: up 1030.94% in 2023, down 2053.54% in 2023.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$6.4 million in 2021, then surged by 32.05% to -$4.3 million in 2022, then plummeted by 2053.54% to -$93.3 million in 2023, then soared by 77.77% to -$20.7 million in 2024, then soared by 339.0% to $49.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were $49.6 million in Q4 2025, $18.1 million in Q3 2025, and $35.6 million in Q2 2025.